Navigation Links
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Date:4/30/2008

here is currently no FDA-approved therapy for treating cancer cachexia.

VT-122 is an oral, multi-targeted, chrono-modulated, fixed dose combination of propranolol and etodolac. Vicus chose the constituent drugs based on the results of its cancer cachexia disease model that predicted blocking systemic inflammation would reverse the wasting process. The use of this combination was initially assessed in investigator-led pilot trials. Data obtained from a total of nine evaluable subjects demonstrated reversal of rapid weight loss in seven subjects. No treatment related serious adverse events were reported.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held biopharmaceutical company focused on developing oncology supportive care drug products for serious unmet medical needs. These products include: VT-122, in Phase 2 clinical trials, for cancer cachexia; VT-211 and VT-212, in investigator-led pilot trials, for chemotherapy-induced oral mucositis and neutropenia; and VT-310, in pre-clinical evaluation, for cancer-related fatigue. Each product candidate is a novel combination and dosing regimen of two generic drugs with known safety profiles. The constituent drugs and dosing regimens are chosen based on the results of Vicus' predictive disease models and the company's understanding of the body's maladaptive response to cancer and its treatment.

Website: http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
3. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
7. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
11. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)..., Nov. 25 Poniard,Pharm...tical company focused on,innovative oncology ther...strategic alternatives for its preclinical researc... its resources on the clinical development of pico...t the initial commercialization of,picoplatin in ...
(Date:11/25/2008)...ire-FirstCall/ -- CardioVascular,BioTherapeutics,...that it has,dosed the first patient in North Amer...rial to treat patients with severe coronary heart ...t of CORonary heart Disease) trial will include,f...oses in approximately 120,patients with severe co...
(Date:11/24/2008)...PRNewswire-FirstCall/ -- Leaders of Schering-Ploug...ate for investors on the company,s research pipeli...hat includes 46 new entities in clinical trials or...dies. , , "Research and development is addi...ontinue our transformation," said Fred Hassan, cha...
(Date:11/24/2008)...day Unveils Rich Development Pipeline of Compounds...ORTH, N.J., Nov. 24 Sche...led top-line results of a long-term Phase III clin...S(TM) (asenapine) demonstrating efficacy and safet... trial, asenapine was statistically significantly ...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Hear Indiana Announces Talk Walk Run 2008 18272 1Hear Indiana Announces Talk Walk Run 2008 18272 2Hear Indiana Announces Talk Walk Run 2008 18272 3Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 1Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 1Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 3GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 1GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 2GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 3
... /PRNewswire/ -- Results of the,Option (TOcilizuma...ers) trial, the first multinational Phase III stud...ith Actemra (either 4mg/kg,or 8mg/kg) plus methotr...ant improvement in the signs and symptoms of moder...o patients treated with,placebo and methotrexate, ...
...Biotech (OMX Nordic: ACTI) presented,pre-clinical ...The,European League Against Rheumatism, <a target=...rg ) conference, June,13-16*. , "The new pre-clin...nt inhibitory effect on disease development in an,... commented Sven,Andréasson, President &...
Other Medicine Technology:Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: